UCB’s Bimzelx elicited significantly stronger joint relief at 16 weeks than AbbVie’s Skyrizi in a Phase 3 head-to-head study ...
While both Beam Therapeutics and Wave Life Sciences touted notable biomarker benefits for their respective alpha-1 ...
BioSpace analyzed the pay ratio across 10 major pharmaceutical companies to determine which CEOs were paid the most relative ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results